Oracle Buys Drug Trial Software Firm (ORCL)

Photo of Paul Ausick
By Paul Ausick Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Oracle Corp. (NASDAQ: ORCL) has announced that it will acquire ClearTrial, a maker of cloud-based Clinical Trial Operations applications for an undisclosed sum. The transaction is expected to close in the first half of this year. The companies will continue to operate separately until the transaction is closed according to the Oracle announcement.

ClearTrial’s clinical trial applications “will add leading budgeting, forecasting, and analytics capabilities that help plan, source, and track clinical projects,” according to an Oracle overview of the transaction. Oracle plans to integrate ClearTrial’s solutions into its Health Sciences applications portfolio.

Oracle shares are trading down fractionally at $29.34 in a 52-week range of $24.72-$36.50.

Contact [email protected] for any questions or corrections.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Top Gaining Stocks

PYPL Vol: 91,051,931
BLK Vol: 1,583,086
CBRE Vol: 1,908,902
KMX Vol: 4,715,131
IVZ Vol: 6,265,161

Top Losing Stocks

PNR Vol: 12,047,011
ERIE Vol: 641,455
DELL Vol: 13,041,473
PGR Vol: 7,223,690
WDC Vol: 7,926,134